Evaluation of bone health in childhood is important to identify children who have inadequate bone mineralisation and who may benefit from interventions to decrease their risk of osteoporosis and subsequent fracture. There are no bone protective agents that are licensed specifically for the prevention and treatment of osteoporosis in children. In this review, we discuss the mechanism of action and use of bisphosphonates and other new and established bone protective agents in children.
- bone disease
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors CW wrote the first draft, SFA edited and approved the final version.
Funding CW and SFA: Medical Research Council and Muscular Dystrophy UK MR/N020588/1, SFA: Chief Scientist Office CAF/DMD/14/01.
Competing interests SFA: diurnal research grant, Novo Nordisk (data monitoring board and educational meetings), Kyowa Kirin (consultancy).
Provenance and peer review Commissioned; externally peer reviewed.